CDMO Hovione said that it is investing $170 million to increase overall capacity at its manufacturing facilities in Portugal, Ireland, and the US by about 25% to meet strong demand. According to the company, its facilities expansion coincides with the addition of about 300 positions to its workforce. Hovione, which offers a full range of development and manufacturing services for dry powder inhalation products, has previously announced several expansions of its facilities over the past few years.
The newly announced expansion includes added production capability for high potency API manufacturing in Portugal and Ireland and a new 2900 sq m building at the US site in New Jersey. The US site is expected to have added commercial scale spray drying capacity come online by 2023, and commercial spray dryers are being added at the Irish and Portuguese sites as well.
Hovione CEO Guy Villax commented, “Hovione is in it for life and what better way to manifest this than through expansion of our global capacity and capabilities. Our sustainable organic growth strategy will allow us to keep true to those values that have been guiding us for more than 60 years.”
Chief Operation Officer Jean-Luc Herbeaux said, “These investments reinforce our integrated specialized offer globally, providing our clients with a line of sight for their projects. Focus is placed on facilitating and speeding up the drug development cycle and launch, by providing API manufacturing, particle engineering, and tableting services in each site. Our strategy continues to be to grow organically via investments in our existing sites, which are designed for purpose. This reduces the complexity associated with the growth journey and allows us to focus our management attention on what counts most, i.e. guaranteeing that our clients go to market with quality, safe and effective medicines for their patients.”
Read the Hovione press release.
